Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

Subjects:

Variations in slope utilization by a female red panda across different time periods and in comparison with their wild individuals. Different capital letters indicated significant d... by Yanshan Zhou (14131359)

Subjects:

Variations in altitude utilization by a female red panda across different time periods and in comparison with wild individuals. Different capital letters indicated significant diff... by Yanshan Zhou (14131359)

Subjects:

Variations in aspect utilization by a female red panda across different time periods and in comparison with wild individuals. Different capital letters indicated significant differ... by Yanshan Zhou (14131359)

Subjects:

Growth of certain cancer cell lines requires IRE1 but not its enzymatic activity. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

Dataset in. CSV. by Kare Chawicha Debessa (20660605)

“…Of these, 77 women (9%) dropped from the CBHI scheme (AOR = 9; 95% CI: 7.43% −11.38%; p < 0.001). Lower dropout likelihood was significantly associated with increased age (AOR = 0.93; 95% CI: 0.89–0.97; p < 0.001) and larger family size (AOR = 0.28; 95% CI: 0.17–0.50; p < 0.001).…”

Ba/F3 EML4-ALK^mutants exhibit variable dose-response to ABT-199 treatment. by Richard Junior Zapata Dongo (17912565)

Spearman’s correlation coefficients between mean scores of each S-Hab-Q factor and the AQ subscales. by Vincenza Tarantino (182506)